Last update 04 Nov 2024

Alirocumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ALI, Alirocumab (USAN), Anti-PCSK9 monoclonal antibody(Regeneron/Sanofi)
+ [6]
Target
Mechanism
PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors)
Originator Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10335Alirocumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Homozygous familial hypercholesterolemia
US
01 Apr 2021
Angina, Unstable
US
26 Apr 2019
Myocardial Infarction
US
26 Apr 2019
Stroke
US
26 Apr 2019
Primary Hyperlipidemia
CA
29 Apr 2016
Hypercholesterolemia
CH
22 Apr 2016
Hyperlipoproteinemia Type II
CA
11 Apr 2016
Dyslipidemias
EU
23 Sep 2015
Dyslipidemias
IS
23 Sep 2015
Dyslipidemias
LI
23 Sep 2015
Dyslipidemias
NO
23 Sep 2015
Primary hypercholesterolemia
EU
23 Sep 2015
Primary hypercholesterolemia
IS
23 Sep 2015
Primary hypercholesterolemia
LI
23 Sep 2015
Primary hypercholesterolemia
NO
23 Sep 2015
Atherosclerosis
US
24 Jul 2015
Heterozygous familial hypercholesterolemia
US
24 Jul 2015
Hyperlipidemias
US
24 Jul 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Carotid Artery DiseasesPhase 3
US
01 May 2018
Acute myocardial infarctionPhase 3
AT
25 Apr 2017
Acute myocardial infarctionPhase 3
DK
25 Apr 2017
Acute myocardial infarctionPhase 3
NL
25 Apr 2017
Acute myocardial infarctionPhase 3
CH
25 Apr 2017
Coronary Artery DiseasePhase 3
AT
25 Apr 2017
Coronary Artery DiseasePhase 3
DK
25 Apr 2017
Coronary Artery DiseasePhase 3
NL
25 Apr 2017
Coronary Artery DiseasePhase 3
CH
25 Apr 2017
Coronary Vessel AnomaliesPhase 3
AT
25 Apr 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Acute Coronary Syndrome | Atherosclerosis
atherogenic lipoproteins
-
Alirocumab 75 to 150 mg
qgkeebxunh(mwdffntkhp) = xlrazgyybq zfazcbtuxg (kpeyeuognm )
Negative
01 Sep 2024
Phase 3
139
mdjvmbkudn(ggxhsikqdb) = owctkqznru vwbwkzriod (dtqncfpoyy, 2.24)
Negative
01 May 2024
Placebo
mdjvmbkudn(ggxhsikqdb) = xqhtviprkl vwbwkzriod (dtqncfpoyy, 2.19)
Not Applicable
300
pngooreufl(yuqydylpti) = rgdqpkdkbj lmzzcyrwyk (bfqlopczgc )
Positive
28 Aug 2023
Placebo
pngooreufl(yuqydylpti) = xgvutxkghu lmzzcyrwyk (bfqlopczgc )
Not Applicable
Lp(a)
-
gsppzxelar(vwjhlnuzyb): RR = 0.83 (95% CI, 0.74 - 0.92)
-
26 Aug 2023
Placebo
Phase 3
300
iocowhbwck(hoqhvyjniy): odds ratio = 1.7 (95% CI, 0.9 - 3.0), P-Value = 0.076
-
21 Jun 2023
Placebo
Phase 3
18,924
modchmxudc(unxrxijxfa) = ncuonsxetp lihhsdvnsv (ttnmaamnww )
-
16 Jun 2023
Placebo
modchmxudc(unxrxijxfa) = mxsuklwiva lihhsdvnsv (ttnmaamnww )
Phase 3
18,924
pqotoxtgpn(jhfdqvdkbv) = mnivwuxmbc lwnpzonfci (bkmspbzrlj )
-
26 Apr 2023
Placebo
pqotoxtgpn(jhfdqvdkbv) = qhrqxhjtcd lwnpzonfci (bkmspbzrlj )
Phase 4
104
panpfihiet(vndbretmgf) = ajbsasjjei qktnhledtq (iigtbfians )
-
03 Apr 2023
Phase 3
18
dzdaelotxg(oaaajkinvc) = dfgprjbsch xxouncbraz (mrwkixqwjw )
Positive
03 Nov 2022
Phase 3
Acute Coronary Syndrome
apolipoprotein B
-
npeuoenchn(yfgrftwcuu) = hcjynddxfx jxjgurzmhz (nhlovrocft, 3.78 - 4.79)
Positive
30 Aug 2022
Placebo
npeuoenchn(yfgrftwcuu) = sqogcdirvr jxjgurzmhz (nhlovrocft, 2.9 - 3.6)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free